Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of GKT137831 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Setanaxib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Biomarker; Pharmacodynamics
- Acronyms GKT137831
- 04 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 Jan 2025.
- 04 Apr 2024 Planned primary completion date changed from 1 Apr 2024 to 30 Nov 2024.
- 05 Apr 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.